Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Eurazeo ( (FR:RF) ) has provided an update.
Eurazeo has led a €29 million Series B fundraising for Germitec, a French MedTech company specializing in High-Level Disinfection solutions for ultrasound probes. This investment is part of Eurazeo’s commitment to strengthening its position in the healthcare industry and supporting the expansion of Germitec’s innovative, environmentally friendly technology, especially in the United States where Germitec recently received FDA De Novo certification. The move highlights Eurazeo’s strategic focus on healthcare innovation and the prevention of healthcare-associated infections, advancing both public health solutions and French healthcare sovereignty.
More about Eurazeo
Eurazeo is an investment company with a focus on the strategic healthcare sector, particularly in Europe. Through its Nov Santé Actions Non Cotées Fund and its Health Venture subsidiary, Kurma Partners, Eurazeo aims to support innovation and the emergence of industrial leaders in healthcare by investing in growth equity opportunities.
YTD Price Performance: 10.99%
Average Trading Volume: 18,933
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €5.88B
Find detailed analytics on RF stock on TipRanks’ Stock Analysis page.
